Abstract| Volume 37, 101571, January 2020

Evaluation of Glucose-6-Phosphate Dehydrogenase Serum Level in Multiple Sclerosis and Neuromyelitis Optica Patients

      Multiple sclerosis (MS) and Neuromyelitis Optica (NMO) are both demyelinating disorders and oxidative stress is suggested to have a role in their pathogenesis. Glucose 6 phosphate dehydrogenase (G6PD) produces nicotinamide adenine dinucleotide phosphate (NADPH) via the pentose phosphate pathway. NADPH is not only involved in the synthesis of fatty acids necessary for myelination but also it is involved in the defense against oxidative stress. Prescribing Supplementary Vitamin D as a part of the MS treatment plan can increase G6PD gene expression. The aim of this study is to determine the serum level of G6PD in MS and NMO patients and its relationship with vitamin D since it is yet to be explored thoroughly.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect